Sanjay Chanda - Net Worth and Insider Trading

Sanjay Chanda Net Worth

The estimated net worth of Sanjay Chanda is at least $285,634 dollars as of 2024-11-13. Sanjay Chanda is the SVP, Drug Development of Anacor Pharmaceuticals Inc and owns about 29,087 shares of Anacor Pharmaceuticals Inc (ANAC) stock worth over $285,634. Details can be seen in Sanjay Chanda's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Sanjay Chanda has not made any transactions after 2015-03-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Sanjay Chanda

To

Sanjay Chanda Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sanjay Chanda owns 1 companies in total, including AN2 Therapeutics Inc (ANTX) .

Click here to see the complete history of Sanjay Chanda’s form 4 insider trades.

Insider Ownership Summary of Sanjay Chanda

Ticker Comapny Transaction Date Type of Owner
ANTX AN2 Therapeutics Inc 2022-03-24 Chief Development Officer

Sanjay Chanda Latest Holdings Summary

Sanjay Chanda currently owns a total of 1 stock. Sanjay Chanda owns 29,087 shares of Anacor Pharmaceuticals Inc (ANAC) as of March 4, 2015, with a value of $285,634.

Latest Holdings of Sanjay Chanda

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ANAC Anacor Pharmaceuticals Inc 2015-03-04 29,087 9.82 285,634

Holding Weightings of Sanjay Chanda


Sanjay Chanda Form 4 Trading Tracker

According to the SEC Form 4 filings, Sanjay Chanda has made a total of 0 transactions in Anacor Pharmaceuticals Inc (ANAC) over the past 5 years. The most-recent trade in Anacor Pharmaceuticals Inc is the sale of 5,000 shares on March 4, 2015, which brought Sanjay Chanda around $225,000.

Insider Trading History of Sanjay Chanda

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sanjay Chanda Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Sanjay Chanda Ownership Network

Ownership Network List of Sanjay Chanda

No Data

Ownership Network Relation of Sanjay Chanda

Insider Network Chart

Sanjay Chanda Owned Company Details

What does AN2 Therapeutics Inc do?

Who are the key executives at AN2 Therapeutics Inc?

Sanjay Chanda is the Chief Development Officer of AN2 Therapeutics Inc. Other key executives at AN2 Therapeutics Inc include 10 percent owner Ra Capital Healthcare Fund Lp , 10 percent owner Adjuvant Global Health Technology Fund De, L.p. , and Chief Strategy Officer Kevin Michael Krause .

AN2 Therapeutics Inc (ANTX) Insider Trades Summary

Over the past 18 months, Sanjay Chanda made no insider transaction in AN2 Therapeutics Inc (ANTX). Other recent insider transactions involving AN2 Therapeutics Inc (ANTX) include a net sale of 223,880 shares made by Adjuvant Global Health Technology Fund De, L.p. , a net sale of 223,880 shares made by Kabeer Aziz , and a net sale of 1,747,316 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 0 shares of AN2 Therapeutics Inc (ANTX) in total and bought 1,500,000 shares, with a net purchase of 1,500,000 shares. During the past 18 months, 4,090,725 shares of AN2 Therapeutics Inc (ANTX) were sold and 3,287,778 shares were bought by its insiders, resulting in a net sale of 802,947 shares.

AN2 Therapeutics Inc (ANTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

AN2 Therapeutics Inc Insider Transactions

No Available Data

Sanjay Chanda Mailing Address

Above is the net worth, insider trading, and ownership report for Sanjay Chanda. You might contact Sanjay Chanda via mailing address: C/o Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto Ca 94303.